1660 related articles for article (PubMed ID: 17379060)
1. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
2. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
Sankaranarayanan J; Puumala SE
Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
[TBL] [Abstract][Full Text] [Related]
4. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
7. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
8. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
9. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
10. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
11. Utilization of, and adherence to, drug therapy among medicaid beneficiaries with congestive heart failure.
Bagchi AD; Esposito D; Kim M; Verdier J; Bencio D
Clin Ther; 2007 Aug; 29(8):1771-83. PubMed ID: 17919558
[TBL] [Abstract][Full Text] [Related]
12. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
13. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
15. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Boaz TL; Constantine RJ; Robst J; Becker MA; Howe AM
J Clin Psychiatry; 2011 Aug; 72(8):1079-85. PubMed ID: 21034690
[TBL] [Abstract][Full Text] [Related]
16. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
[TBL] [Abstract][Full Text] [Related]
17. [Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment].
Koga M
Seishin Shinkeigaku Zasshi; 2003; 105(4):473-88. PubMed ID: 12806910
[TBL] [Abstract][Full Text] [Related]
18. Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients.
Fontanella CA; Bridge JA; Campo JV
Ann Pharmacother; 2009 Dec; 43(12):1939-47. PubMed ID: 19934394
[TBL] [Abstract][Full Text] [Related]
19. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
20. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
